heart failure reduced EF. Systolic (congestive) heart failure
Conditions
Interventions
Intervention 1: Intervention group: 30 patients with HErEF which are admitted with congestion and decompensated symptoms will receive 40 mg nanocurcumin capsule twice a day for 7 days and standard the
Sponsors
Bagheiat-allah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with reduced EF heart failure Signing an informed consent form
Exclusion criteria
Exclusion criteria: No history of rheumatologic disease No active infection No acute kidney injury
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Interleukin 6. Timepoint: At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: Laboratory tests.;NT-proBNP. Timepoint: At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: Laboratory tests. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum creatinine. Timepoint: At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: laboratory tests.;WBC count. Timepoint: En At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: laboratory tests.;ALT. Timepoint: At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: laboratory tests.;AST. Timepoint: At the beginning of the study and after receiving the last dose of nanocurcumin. Method of measurement: laboratory tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEmadoddin Hosseinjani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed